LENZ Therapeutics (LENZ) Cash from Restructuring (2024)
LENZ Therapeutics (LENZ) posted quarterly Cash from Restructuring of -$4.8 million for Q2 2024, down 199.13% quarter-over-quarter from $4.8 million in Q1 2024.
LENZ Therapeutics (LENZ) Cash from Restructuring (2024) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Cash from Restructuring for 1 consecutive years, with -$4.8 million the latest figure, recorded in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | LENZ Therapeutics | 148.71 Mn | 148.71 Mn | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -4.77 Mn |
| Mar 31, 2024 | 4.82 Mn |